Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $35.40.
Several research firms have issued reports on LENZ. William Blair upgraded LENZ Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. HC Wainwright restated a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Finally, Raymond James started coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They issued an "outperform" rating and a $37.00 price target for the company.
Check Out Our Latest Analysis on LENZ
LENZ Therapeutics Trading Up 0.6 %
NASDAQ:LENZ traded up $0.19 during trading hours on Friday, reaching $30.97. 85,418 shares of the company's stock were exchanged, compared to its average volume of 135,035. LENZ Therapeutics has a 12 month low of $14.42 and a 12 month high of $38.93. The business's 50-day simple moving average is $31.07 and its two-hundred day simple moving average is $24.57.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. During the same period last year, the company posted ($1.33) EPS. On average, research analysts anticipate that LENZ Therapeutics will post -2.09 EPS for the current fiscal year.
Institutional Trading of LENZ Therapeutics
Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in LENZ Therapeutics in the third quarter valued at about $107,000. MetLife Investment Management LLC acquired a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at about $182,000. GSA Capital Partners LLP bought a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at approximately $246,000. Squarepoint Ops LLC acquired a new position in LENZ Therapeutics in the second quarter worth approximately $181,000. Finally, Jane Street Group LLC bought a new position in LENZ Therapeutics during the third quarter valued at approximately $286,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.
About LENZ Therapeutics
(
Get Free ReportLENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Further Reading
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
